Pharmas are cool with YouTube but fear Twitter

Share this article:
Preserve your company's reputation online
Preserve your company's reputation online

Among social media channels, healthcare execs are most comfortable with YouTube and least comfortable with Twitter, a survey suggests.

Ideahaus MarketSMITH Services and Hellebusch Research and Consulting surveyed 107 healthcare professionals (30% from pharmas and biotechs) ranging from CEOs to brand managers and found widespread trepidation about using social media channels absent FDA guidance spelling out the boundaries. That won't surprise anyone, but maybe ought to, nine years after the advent of Facebook and seven years after the first Tweet.

Nearly three out of four respondents (74%) said they'd been conservative in their use of social media to date. Asked about the appropriateness of using different channels, respondents were most comfortable with YouTube (68% called it acceptable, update or no), followed by LinkedIn (62%) and Facebook (60%, even though many abandoned their brand pages on the site after comments were mandated). Respondents were twitchy about text messaging (49%), Twitter (42%) and Flickr (32%).

“Apparently, media and context is another important consideration calling for additional research,” wrote the study's authors. “For example, video (a series of pictures and sound) is more favored while single images are not. A more descriptive and invading media has been selected over other media. Additionally, a common characteristic of YouTube is that of a broadcaster's network while Twitter is regarded as conversational. It may indicate levels of comfort with sharing information but not with engaging in a dialogue.”

Only half think companies should monitor social media sites to understand patient needs, concerns and perceptions.

Respondents were split on whether companies are misusing social media, with a third saying mareters manipulate blogs, chat rooms and discussions, and only 8% say the FDA is adequately managing social media or that it has the resources to do so.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...